Loading
Every dated change on the records linked to Platinum-resistant ovarian cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
First- and second-line metastatic colorectal cancer with fluoropyrimidine-based chemotherapy, only when targeted treatment or immunotherapy is unsuitable
A milestone in how this cancer is treated.
OS 18.
ORR 55.
OS 16.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
FRα-high platinum-resistant ovarian cancer (full approval 2024)
Objective responses in about a third of patients with folate receptor alpha-high platinum-resistant ovarian cancer; accelerated approval in November 2022.
A milestone in how this cancer is treated.
Platinum-resistant ovarian cancer with chemotherapy; recurrent/metastatic cervical cancer with chemotherapy
Median progression-free survival 6.
A milestone in how this cancer is treated.